USD 0.64
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 6.52 Billion USD | 8.68% |
2022 | 6 Billion USD | 10.16% |
2021 | 5.44 Billion USD | 18.52% |
2020 | 4.59 Billion USD | 21.7% |
2019 | 3.77 Billion USD | 12.12% |
2018 | 3.36 Billion USD | 22.28% |
2017 | 2.75 Billion USD | 44.75% |
2016 | 1.9 Billion USD | 8.97% |
2015 | 1.74 Billion USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 6.59 Billion USD | 0.0% |
2024 Q1 | - USD | -100.0% |
2023 Q3 | - USD | -100.0% |
2023 Q1 | - USD | -100.0% |
2023 Q2 | 6.01 Billion USD | 0.0% |
2023 Q4 | 6.52 Billion USD | 0.0% |
2023 FY | 6.52 Billion USD | 8.68% |
2022 Q4 | 6 Billion USD | 0.0% |
2022 FY | 6 Billion USD | 10.16% |
2022 Q2 | 5.79 Billion USD | 0.0% |
2021 Q2 | 5.08 Billion USD | 0.0% |
2021 FY | 5.44 Billion USD | 18.52% |
2021 Q4 | 5.44 Billion USD | 0.0% |
2020 FY | 4.59 Billion USD | 21.7% |
2020 Q4 | 4.59 Billion USD | 0.0% |
2020 Q2 | 4.12 Billion USD | 0.0% |
2019 FY | 3.77 Billion USD | 12.12% |
2019 Q2 | 3.54 Billion USD | 0.0% |
2019 Q4 | 3.77 Billion USD | 0.0% |
2018 FY | 3.36 Billion USD | 22.28% |
2017 FY | 2.75 Billion USD | 44.75% |
2016 FY | 1.9 Billion USD | 8.97% |
2015 FY | 1.74 Billion USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AstraZeneca PLC | 100.97 Billion USD | 93.539% |
Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 93.144% |
Clarus Therapeutics Holdings, Inc. | 51.7 Million USD | -12517.03% |
Novartis AG | 99.94 Billion USD | 93.472% |
PT Kalbe Farma Tbk. | 1.75 Billion USD | -270.948% |